FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

Similar Items

• FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
  od: Summers, Jeff, i dr.
  Izdano: (2010)
• FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma
  od: Nair, Abhilasha, i dr.
  Izdano: (2020)
• FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
  od: Fashoyin‐Aje, Lola, i dr.
  Izdano: (2018)
• FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
  od: Kasamon, Yvette L., i dr.
  Izdano: (2017)
• FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
  od: Larkins, Erin, i dr.
  Izdano: (2017)